Parkinson's Disease (PD)

Neurology
13
Pipeline Programs
4
Companies
21
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
12
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
ABBV-951Phase 35 trials
Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral TherapyN/A1 trial
Active Trials
NCT02381444Completed136Est. Jan 2020
NCT06107426Recruiting450Est. May 2029
NCT05916157Recruiting250Est. Jul 2026
+3 more trials
Bial
BialPortugal - Coronado
10 programs
10
BIA 3-202Phase 11 trial
BIA 9-1067Phase 11 trial
BIA 9-1067Phase 11 trial
BIA 9-1067Phase 11 trial
BIA 9-1067Phase 11 trial
+5 more programs
Active Trials
NCT02778594CompletedEst. Nov 2005
NCT02169440CompletedEst. Jul 2009
NCT02170376CompletedEst. Jan 2012
+7 more trials
AC Immune
AC Immune1015 LAUSANNE, Switzerland
1 program
1
[18F]ACI-15916Phase 11 trial
Active Trials
NCT06891703RecruitingEst. Mar 2026
M&
Merck & Co.RAHWAY, NJ
1 program
1
[18F]MK-0947Phase 11 trial
Active Trials
NCT07348250Recruiting22Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AbbVieABBV-951
AbbVieABBV-951
AbbVieABBV-951
Merck & Co.[18F]MK-0947
AC Immune[18F]ACI-15916
AbbVieABBV-951
AbbVieABBV-951
AbbVieABBV-951
BialBIA 9-1067
BialOPC
BialBIA 9-1067 5 mg
BialBIA 9-1067
BialBIA 9-1067
BialBIA 9-1067
BialBIA 9-1067

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 1,415 patients across 21 trials

NCT04750226AbbVieABBV-951

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Start: Feb 2021Est. completion: Apr 2026118 patients
Phase 3Active Not Recruiting
NCT04379050AbbVieABBV-951

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Start: Jun 2020Est. completion: Apr 2026130 patients
Phase 3Active Not Recruiting
NCT03781167AbbVieABBV-951

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Start: Apr 2019Est. completion: Aug 2022244 patients
Phase 3Completed
NCT07348250Merck & Co.[18F]MK-0947

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

Start: Dec 2025Est. completion: Dec 202622 patients
Phase 1Recruiting
NCT06891703AC Immune[18F]ACI-15916

[18F]ACI-15916 PET in α-synucleinopathies

Start: Mar 2025Est. completion: Mar 2026
Phase 1Recruiting
NCT05094050AbbVieABBV-951

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Start: Jan 2022Est. completion: Mar 202316 patients
Phase 1Completed
NCT03374917AbbVieABBV-951

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Start: Apr 2018Est. completion: Mar 201920 patients
Phase 1Completed
NCT03033498AbbVieABBV-951

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Start: May 2017Est. completion: Jun 201929 patients
Phase 1Completed
NCT02170376BialBIA 9-1067

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Start: Sep 2011Est. completion: Jan 2012
Phase 1Completed
NCT02169427BialOPC

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Start: Mar 2011Est. completion: Jul 2011
Phase 1Completed
NCT02169414BialBIA 9-1067 5 mg

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Start: Feb 2010Est. completion: Jul 2010
Phase 1Completed
NCT02169440BialBIA 9-1067

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Start: Jun 2009Est. completion: Jul 2009
Phase 1Completed
NCT02169466BialBIA 9-1067

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Start: Jan 2009Est. completion: May 2009
Phase 1Completed
NCT02169453BialBIA 9-1067

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Start: Oct 2008Est. completion: Jan 2009
Phase 1Completed
NCT02169895BialBIA 9-1067

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Start: Sep 2008Est. completion: Nov 2008
Phase 1Completed
NCT02169479BialBIA 9-1067

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Start: Sep 2008Est. completion: Dec 2008
Phase 1Completed
NCT02071810BialBIA 9-1067

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Start: Apr 2008Est. completion: Sep 2008
Phase 1Completed
NCT02778594BialBIA 3-202

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Start: Sep 2005Est. completion: Nov 2005
Phase 1Completed
NCT06107426AbbVieABBV-951

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Start: Jan 2024Est. completion: May 2029450 patients
N/ARecruiting
NCT05916157AbbVieABBV-951

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

Start: Nov 2023Est. completion: Jul 2026250 patients
N/ARecruiting
NCT02381444AbbVieHealth Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

Start: Apr 2015Est. completion: Jan 2020136 patients
N/ACompleted

Related Jobs in Neurology

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
5h ago
$208K - $234K/yr

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
5h ago

Director of Medical Affairs

CoMind
Miami, FL
6h ago

Director of Finance

CoMind
London, UK
6h ago

Electronics Engineering Manager

CoMind
London, UK
6h ago

Director of Information Technology

Zavation Medical Products
6h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 1,415 patients
4 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)